IQVIA CEO to Address Leerink 2026 Conference
RESEARCH TRIANGLE PARK, N.C., March 2, 2026 IQVIA Holdings Inc. (NYSE: IQV) announced that Chairman and Chief Executive Officer...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RESEARCH TRIANGLE PARK, N.C., March 2, 2026 IQVIA Holdings Inc. (NYSE: IQV) announced that Chairman and Chief Executive Officer...
CAMBRIDGE, Mass. | January 8, 2026 — Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibody therapies, announced the...
SAN DIEGO | January 8, 2026 — Just – Evotec Biologics, a collaboration between Evotec SE and Just –...
Laupheim and Martinsried, Germany, December 2, 2025 — Rentschler Biopharma, a global contract development and manufacturing organization, and Coriolis...
